Repros Therapeutics Inc. (NASDAQ:RPRX) shares were down 4.4% during mid-day trading on Tuesday . The company traded as low as $2.12 and last traded at $2.18, with a volume of 204,995 shares trading hands. The stock had previously closed at $2.28.

Separately, Zacks Investment Research upgraded Repros Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Tuesday. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $2.25.

The firm has a 50-day moving average of $1.85 and a 200-day moving average of $1.61. The firm’s market capitalization is $52.28 million.

Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.02. Analysts anticipate that Repros Therapeutics Inc. will post ($0.70) earnings per share for the current fiscal year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.